More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$9.37B
EPS
-1.1
P/E ratio
--
Price to sales
2.56
Dividend yield
0.326%
Beta
1.262956
Previous close
$60.62
Today's open
$60.38
Day's range
$60.03 - $62.22
52 week range
$32.37 - $68.98
show more
CEO
Frank H. Laukien
Employees
11085
Headquarters
Billerica, MA
Exchange
Nasdaq Global Select
Shares outstanding
152722385
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Here's Why Bruker (BRKR) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research • Nov 17, 2026

Bruker Announces that Institute Director, Biopharma Entrepreneur and Immunology Leader Dr. Eicke Latz will join its Board of Directors
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors is adding Eicke Latz, MD PhD to serve on its board of directors, effective as of January 1, 2027. Dr. Latz is an internationally recognized medical institute director, physician-scientist, successful biopharma entrepreneur, and innovation leader. His work is transforming the understanding of innate immunity and inflammation, while also advancing numerous therapeutic programs from disc.
Business Wire • Nov 16, 2026

Should You Continue to Retain Bruker Stock in Your Portfolio?
BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.
Zacks Investment Research • Nov 13, 2026

Bruker: Five Quarters Of Orders Are Still Waiting To Show Up In Revenue
Bruker is positioned for a 2027 operating leverage cycle, with five consecutive quarters of bookings exceeding revenue and significant cost reductions. BRKR's margin expansion is driven by self-help initiatives, not volume, with non-GAAP operating margin rising to 16.3% and free cash flow rebounding sharply. Management expects backlog conversion to drive mid-single-digit organic growth and double-digit EPS expansion in 2027, supported by portfolio shifts toward drug discovery.
Seeking Alpha • Nov 7, 2026

Bruker Q3 Earnings Call Highlights
Bruker NASDAQ: BRKR reported third-quarter 2026 revenue growth of 1.6% to $874 million, while non-GAAP earnings per share rose 24.4% year over year to $0.56 as cost-saving actions and favorable product mix supported margin expansion.
MarketBeat • Nov 4, 2026

Bruker Corporation (BRKR) Q3 2026 Earnings Call Transcript
Bruker Corporation ( BRKR ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Joe Kostka Frank Laukien - Chairman, CEO & President Gerald Herman - Executive VP & CFO Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Luke Sergott - Barclays Bank PLC, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Lu Li - BofA Securities, Research Division Douglas Schenkel - UBS Investment Bank, Research Division Jack Meehan - Operon Research, LLC Kyle Boucher - TD Cowen, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Albert Hu - CTBC Financial Holding Co., Ltd. Presentation Operator Good morning, everyone, and welcome to the Bruker Corporation Third Quarter 2026 Earnings Conference Call.
Seeking Alpha • Nov 4, 2026

Bruker Reports Third Quarter 2026 Financial Results
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three and nine months ended September 30, 2026. Frank H. Laukien, Bruker's President and CEO, commented: “Bruker drives significant advances in post-genomic drug discovery and disease biology research, from proteoforms to glycobiology, and from functional protein interactions to spatial biology. These deeper insights into molecular, cell and tissue biology are foundational for successf.
Business Wire • Nov 4, 2026

Bruker (BRKR) Q3 Earnings and Revenues Surpass Estimates
Bruker (BRKR) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.45 per share a year ago.
Zacks Investment Research • Nov 4, 2026

Here's What Key Metrics Tell Us About Bruker (BRKR) Q3 Earnings
Although the revenue and EPS for Bruker (BRKR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 4, 2026

Wayfair, Lendingtree, Bruker, Zimmer Biomet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining around 1,100 points on Wednesday.
Benzinga • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Bruker Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.